Veracyte Inc. (VCYT)
31.14
-0.39 (-1.24%)
At close: Apr 17, 2025, 3:59 PM
-1.24% (1D)
| Bid | 30.01 |
| Market Cap | 2.43B |
| Revenue (ttm) | 445.76M |
| Net Income (ttm) | 24.14M |
| EPS (ttm) | 0.31 |
| PE Ratio (ttm) | 100.45 |
| Forward PE | 44.53 |
| Analyst | Buy |
| Ask | 31.59 |
| Volume | 697,680 |
| Avg. Volume (20D) | 966,582 |
| Open | 31.28 |
| Previous Close | 31.53 |
| Day's Range | 30.81 - 31.31 |
| 52-Week Range | 19.02 - 47.32 |
| Beta | 2.04 |
About VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 30, 2013
Employees 824
Stock Exchange NASDAQ
Ticker Symbol VCYT
Website https://www.veracyte.com
Analyst Forecast
According to 9 analyst ratings, the average rating for VCYT stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 41.30% from the latest price.
Stock ForecastsNext Earnings Release
Veracyte Inc. is scheduled to release its earnings on May 7, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+0.46%
Veracyte shares are trading lower. The company rep...
Unlock content with
Pro Subscription
5 months ago
+2.05%
Veracyte shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance. Needham and UBS maintained Buy ratings and raised their respective price targets on the stock.
